An improved response to anti‐angiogenic therapy in cancer types with low NRP1 expression could be dependent on the preferential formation of VEGFR2/NRP1 cis‐complexes within the endothelium, promoting angiogenesis, which would be blocked by bevacizumab. This evidence concerns the gene NRP1 and cancer.